Skip to Main content Skip to Navigation
New interface
Journal articles

Prévention de la fibrose et du cancer du foie liés au virus de l’hépatite B en Afrique

Abstract : Despite the existence of an effective vaccine, HBV infects 257 million people worldwide and is the cause of the majority of HCC. With an annual mortality rate of 887 000 patients in 2015, this cancer is the second deadliest. Low-income countries such as ones in sub-Saharan Africa are the most at risk due to the limited access to healthcare. To overcome this and born from an international research collaboration within an EU project, the Prolifica study aimed at evaluating a screen-and-treat program to prevent HBV complications, and more particularly HCC. Based on communities, facilities and hospitals HBsAg+ detection, the study lasted from 2011 to 2016. From the "cost effectiveness" feasibility of such a program to the development of simple scores for antiviral treatment, Prolifica uncovered data of crucial importance in a region with low HBV infection awareness, transmissions modes and prevention means which could have impacts on public health policies.
Document type :
Journal articles
Complete list of metadata

Cited literature [35 references]  Display  Hide  Download
Contributor : Yusuke Shimakawa Connect in order to contact the contributor
Submitted on : Friday, June 19, 2020 - 3:06:49 PM
Last modification on : Tuesday, October 18, 2022 - 4:27:38 AM




Damien Cohen, Yusuke Shimakawa, Gibril Ndow, Amina Sow, Saydiba Tamba, et al.. Prévention de la fibrose et du cancer du foie liés au virus de l’hépatite B en Afrique. médecine/sciences, 2019, 35 (5), pp.431-439. ⟨10.1051/medsci/2019076⟩. ⟨pasteur-02875225⟩



Record views


Files downloads